INNOVADERM CRO IS NOW INDERO.

Stop the Noise! How to Mitigate Placebo Response in Rheumatology Trials – ACR Convergence 2026 Event

Author picture

Indero hosted a well-attended event during the American College of Rheumatology (ACR) Convergence 2026 in Orlando, Florida. The November 9 session brought together biopharma industry leaders for a morning of insight and discussion. This year’s program focused on mitigating placebo response in rheumatology randomized controlled trials (RCTs). 

Key themes:  

  • Mitigation of placebo responses in systemic lupus erythematosus (SLE) RCTs 
  • Placebo responses: What shapes trial results in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) RCTs 

Presenters and panelists: 

  • Joan T. Merrill, MD, MACR, Oklahoma Medical Research Foundation 
  • Andreas Kerschbaumer, MD, PhD, Stanford University and Medical University of Vienna 
  • Juan Ovalles, MD, Senior Director, Rheumatology, Indero 
  • Pina D’Angelo, MSc, Chief Scientific Officer, Indero

 

 

Have questions about CRO services in rheumatology trials? Contact us.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

Fields marked with * are required.